Search clinical trials for: Adoptive immunotherapy

Total 4105 results

Ciusss de L'Est de l'Île de Montréal

Recruiting

Donor-Derived EBV-Specific T Cells for Life Threatening EBV-lymphoma (OLIP-EBV-TCL-01-HMR01)

EBV Associated Lymphoma

Canada
National Cancer Institute (NCI)

Not yet recruiting

Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)

Leukemia, Lymphocytic, Chronic, B-Cell | B-Cell Chronic Lymphocytic Leukemia | B-Lymphocytic Leukemia, Chronic

United States
Corregene Biotechnology Co., Ltd

Not yet recruiting

CRTE7A2-01 TCR-T Cells for HPV-16 Positive Advanced Cancers

Cervical Cancer | Anal Cancer | Head and Neck Cancers | Other Solid Tumors
University of Florida
Oligo Nation, Inc

Not yet recruiting

ADAGiO: Adoptive Cellular Therapy for the TreAtment of Recurrent OliGodendrogliOma (OG) Adult Patients (ADAGiO)

Recurrent Oligodendroglioma | Progressive Oligodendroglioma

United States
Children's National Research Institute

Not yet recruiting

Immunotherapy for Malignant Pediatric Brain Tumors Employing Adoptive Cellular Therapy (IMPACT) (IMPACT)

Brain Tumor
Cancer Research UK
Aleta BioTherapeutics

Recruiting

A Phase I/II Trial of ALETA-001 for the Treatment of Participants With B-cell Malignancies

Lymphoma, Follicular | Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell

United Kingdom
CARGO Therapeutics

Recruiting

A Phase 2 Study of CRG-022 in Patients With Relapsed/Refractory Large B-cell Lymphoma

Cancer | Relapsed/Refractory Large B-cell Lymphoma (LBCL)

United States
University Health Network, Toronto
Takara Bio Inc.

Recruiting

Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

Relapsed or Refractory Chronic Lymphocytic Leukemia | Relapsed or Refractory Small Lymphocytic Lymphoma | Relapsed or Refractory CD19+ B-cell Lymphoma

Canada
Neogap Therapeutics AB
Karolinska University Hospital; CTC Clinical Trial Consultants AB; Region Västmanland and other collaborators

Recruiting

A First-In-Human Trial of pTTL in Advanced Colorectal Cancer

Colorectal Cancer

Sweden
National Cancer Institute (NCI)

Recruiting

Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignancies

Lymphoma, B-Cell | Chronic Lymphocytic Leukemia | B-Cell Chronic Lymphocytic Leukemia

United States
Christian Hinrichs

Recruiting

E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

Cervical Cancer | HPV-Related Malignancy | Metastatic Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV-Related Cervical Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Christian Hinrichs
National Cancer Institute (NCI)

Not yet recruiting

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

Cervical Cancer | HPV-Related Malignancy | Vulvar Cancer | Anal Cancer | Oropharynx Cancer | Vaginal Cancer | HPV-Related Carcinoma | HPV Positive Oropharyngeal Squamous Cell Carcinoma | Penile Cancer | HPV-Associated Cervical Carcinoma | HPV-Related Adenocarcinoma | HPV-Related Adenosquamous Carcinoma | HPV-Related... and other conditions

United States
Nationwide Children's Hospital
National Pediatric Cancer Foundation

Recruiting

A Multi-Institution Study of TGFβ Imprinted, Ex Vivo Expanded Universal Donor NK Cell Infusions as Adoptive Immunotherapy in Combination With Gemcitabine and Docetaxel in Patients With Relapsed or Refractory Pediatric Bone and Soft Tissue (TINKS)

Pediatric Sarcoma, Refractory | Pediatric Sarcoma, Relapsed

United States
Oncternal Therapeutics, Inc

Recruiting

A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

Relapsed/Refractory Aggressive B-Cell Malignancies

United States
Intima Bioscience, Inc.

Not yet recruiting

CISH Inactivated TILs in the Treatment of NSCLC (CheckCell-2)

Carcinoma, Non-Small-Cell Lung | Adenocarcinoma of Lung | Stage IV Non-small Cell Lung Cancer | Squamous Cell Lung Cancer | Metastatic Non Small Cell Lung Cancer | Large Cell Lung Cancer

United States
Cabaletta Bio

Recruiting

Open-label Study to Evaluate the Safety of Various Dosing Regimens of MuSK-CAART for MuSK Myasthenia Gravis

MuSK Myasthenia Gravis

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
Shanghai Pudong Hospital
Duke University

Recruiting

An Expanded Clinical Study of Triple Therapy for Refractory Solid Tumors That Failed First-line Treatment for Recurrence and Metastasis

Metastatic Cancer | Advanced Cancer

China
Nkarta Inc.

Recruiting

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

Lymphoma, Non-Hodgkin | Waldenstrom Macroglobulinemia | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | B-cell Acute Lymphoblastic Leukemia | Small Lymphocytic Lymphoma | Large B-cell Lymphoma | Indolent Lymphoma | Aggressive Lymphoma | Large-cell Lymphoma

United States, Australia
National Cancer Institute (NCI)

Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
Adicet Bio, Inc

Recruiting

A Phase 1 Study of ADI-001 in B Cell Malignancies (GLEAN-1)

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Mantle-Cell | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal B-cell Lymphoma

United States
Henrik Ditzel
National Board of Health, Denmark; CytoVac A/S

Recruiting

ImmunoBreast - A Phase Ib Study

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer

Denmark
Intima Bioscience, Inc.
Masonic Cancer Center, University of Minnesota

Recruiting

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering

Gastrointestinal Neoplasms | Stomach Cancer | Pancreatic Cancer | Esophageal Cancer | Colon Cancer | Gastrointestinal Cancer | Colo-rectal Cancer | Gall Bladder Cancer | Cancer of Gastrointestinal Tract | Gastrointestinal Epithelial Cancer | Cancer, Gastrointestinal

United States
Cabaletta Bio

Recruiting

Open-label Study to Determine the Maximum Tolerated Dose of DSG3-CAART in Mucosal-dominant PV Patients (mPV)

Mucosal -Dominant Pemphigus Vulgaris

United States
Gregory Daniels
Immunotherapy Foundation

Recruiting

Adoptive Cell Transfer of Autologous Tumor Infiltrating Lymphocytes and High-Dose Interleukin 2 in Select Solid Tumors

Metastatic Melanoma | Metastatic Head and Neck Cancer | Locally Advanced Refractory/Recurrent Melanoma | Locally Advanced Refractory/Recurrent Head and Neck Cancer

United States
Catherine Bollard
M.D. Anderson Cancer Center

Recruiting

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

Viral Infection

United States
National Cancer Institute (NCI)

Recruiting

CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Lymphoma, Non-Hodgkin | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | Acute Lymphoid Leukemia | B-Cell Leukemia | Leukemia, Lymphocytic, B Cell | B-Cell Lymphoma | B-All | B-NHL | B-Non Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Recruiting

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

Breast Cancer | Multiple Myeloma | Ovarian Cancer | Non-Small Cell Lung Cancer | Neuroendocrine Tumors | Gastrointestinal/Genitourinary Cancers | Endocrine Tumors

United States
University of Virginia
Merck Sharp & Dohme LLC

Recruiting

Her2-BATS and Pembrolizumab in Metastatic Breast Cancer (Breast-47)

Metastatic Breast Cancer

United States
Iovance Biotherapeutics, Inc.

Recruiting

Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma

Cervical Carcinoma

United States, Spain, United Kingdom, Germany, France, Italy, Netherlands, Switzerland
Mari Dallas

Recruiting

T Cell Therapy of Opportunistic Cytomegalovirus Infection

Cytomegalovirus Infections | Opportunistic Infections | Hematopoietic Stem Cell Transplant

United States
Loyola University
National Cancer Institute (NCI)

Recruiting

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes

Melanoma

United States
National Cancer Institute (NCI)

Enrolling by invitation

Leukapheresis for CAR or Adoptive Cell Therapy Manufacturing

Lymphoma | Leukemia | Non-Hodgkin's Lymphoma | Acute Lymphoblastic Leukemia | Diffuse Large B Cell Lymphoma

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Institutes of Health (NIH)

Completed

Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation

Hematologic Malignancies | Graft-Versus-Host Disease

United States
National Cancer Institute (NCI)

Active, not recruiting

Prospective Randomized Study of Cell Transfer Therapy for Metastatic Melanoma Using Tumor Infiltrating Lymphocytes Plus IL-2 Following Non-Myeloablative Lymphocyte Depleting Chemo Regimen Alone or in Conjunction With 12Gy Total Body Irradiation (TBI...

Skin Cancer | Metastatic Melanoma

United States
University of Florida
Accelerate Brain Cancer Cure; Lyla Nsouli Foundation

Active, not recruiting

Brain Stem Gliomas Treated With Adoptive Cellular Therapy During Focal Radiotherapy Recovery Alone or With Dose-intensified Temozolomide (Phase I) (BRAVO)

Brain Stem Glioma | Diffuse Intrinsic Pontine Glioma (DIPG)

United States
Technical University of Munich

Completed

Targeted Natural Killer (NK) Cell Based Adoptive Immunotherapy for the Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) After Radiochemotherapy (RCT)

NSCLC Stage IIIA/B

Germany
University of Florida
National Cancer Institute (NCI); National Institutes of Health (NIH); National... and other collaborators

Active, not recruiting

Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas (ACTION)

High Grade Glioma | Malignant Glioma

United States
Instil Bio

Terminated

ITIL-168 in Advanced Melanoma (DELTA-1)

Advanced Cutaneous Melanoma

United States, Canada, United Kingdom
University Hospital, Basel, Switzerland
GMP network of Basel

Completed

Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma (BaseTIL)

Advanced Melanoma

Switzerland
Nkarta Inc.

Active, not recruiting

NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS

MDS | AML, Adult | Relapsed/Refractory AML | Refractory Myelodysplastic Syndromes

United States
National Cancer Institute (NCI)

Active, not recruiting

Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies

Follicular Lymphoma | Acute Lymphoblastic Leukemia | Acute Lymphocytic Leukemia | NHL | B-All | ALL | Large Cell Lymphoma | B-NHL | B-Non Hodgkin Lymphoma | B-precursor ALL

United States
National Cancer Institute (NCI)

Suspended

A Prospective Randomized and Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Melanoma

United States
Monica Thakar

Completed

Phase 2 STIR Trial: Haploidentical Transplant and Donor Natural Killer Cells for Solid Tumors (STIR)

Osteosarcoma | Ewing Sarcoma | Neuroblastoma | Rhabdomyosarcoma | CNS Tumors

United States
National Cancer Institute (NCI)

Withdrawn

Non-Viral TCR Gene Therapy

Breast Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Endocrine/Neuroendocrine | Gastrointestinal/Genitourinary Cancers

United States
Instil Bio

Active, not recruiting

ITIL-306 in Advanced Solid Tumors

Renal Cell Carcinoma | Epithelial Ovarian Cancer | Non-small Cell Lung Cancer

United States
Immatics US, Inc.
M.D. Anderson Cancer Center

Completed

ACTolog in Patients With Solid Cancers (ACTolog)

Cancer | Solid Tumor

United States
Immatics US, Inc.

Completed

TCR-engineered T Cells in Solid Tumors: IMA202-101 (ACTengine)

Cancer | Solid Tumor, Adult | Refractory Cancer | Recurrent Cancer

United States, Germany
GlaxoSmithKline
Merck Sharp & Dohme LLC

Terminated

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Neoplasms

United States, Spain, Netherlands, United Kingdom, Canada
Weill Medical College of Cornell University
New York Blood Center

Terminated

IPA Targeted Adoptive Immunotherapy vs Adult Haplo-identical Cell Infusion During Induction of High Risk Leukemia

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States

Search clinical trials for: Adoptive immunotherapy

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations